mRNA Vaccine Development Expands to Cancer Therapies and Influenza
A new report analyzes the pipeline for mRNA vaccines, highlighting advancements in cancer therapies and influenza vaccines. Moderna and BioNTech are noted as key players in this evolving field.
The messenger RNA (mRNA) vaccine market is seeing significant expansion beyond infectious diseases, with advancements in cancer therapies and influenza vaccines at the forefront, according to a new report by DataM Intelligence. The technology, proven effective during the COVID-19 pandemic, is now being leveraged for a wider range of medical applications.
Moderna is advancing a combination vaccine targeting both COVID-19 and influenza into Phase III trials. The company's pipeline also includes candidates for respiratory syncytial virus (RSV) and bacterial pathogens. BioNTech is focusing on personalized cancer vaccines, with potential approvals anticipated by 2030 and initial therapeutic launches targeted for 2026.
The rapid development and efficacy of mRNA vaccines during the COVID-19 pandemic, such as those from Pfizer-BioNTech and Moderna, underscored the technology's potential. These vaccines not only induced high antibody levels but also a robust T-cell response, crucial for long-term immunity.
The report identifies other major players including Sanofi, GSK plc, AstraZeneca, and Roche exploring mRNA technology. Recent clinical data readouts, such as Moderna's mRNA-1283 COVID-19 vaccine and BioNTech's BNT111 cancer immunotherapy, alongside regulatory designations and strategic collaborations, indicate a strong future trajectory for mRNA-based therapeutics and vaccines.